Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Research & Development (2016 - 2022)

Collegium Pharmaceutical (COLL) has 7 years of Research & Development data on record, last reported at $4.0 million in Q1 2022.

  • For Q1 2022, Research & Development rose 35.94% year-over-year to $4.0 million; the TTM value through Dec 2022 reached $4.0 million, down 57.86%, while the annual FY2022 figure was $4.0 million, 57.86% down from the prior year.
  • Research & Development reached $4.0 million in Q1 2022 per COLL's latest filing, up from $1.6 million in the prior quarter.
  • Across five years, Research & Development topped out at $4.0 million in Q1 2022 and bottomed at $1.4 million in Q3 2021.
  • Average Research & Development over 5 years is $2.5 million, with a median of $2.5 million recorded in 2019.
  • The widest YoY moves for Research & Development: up 38.87% in 2021, down 34.91% in 2021.
  • A 5-year view of Research & Development shows it stood at $2.2 million in 2018, then grew by 6.63% to $2.4 million in 2019, then rose by 3.09% to $2.5 million in 2020, then crashed by 34.91% to $1.6 million in 2021, then skyrocketed by 147.55% to $4.0 million in 2022.
  • Per Business Quant database, its latest 3 readings for Research & Development were $4.0 million in Q1 2022, $1.6 million in Q4 2021, and $1.4 million in Q3 2021.